Predict your next investment

Biofourmis company logo
Corporation
MOBILE & TELECOMMUNICATIONS | Mobile Software & Services / Healthcare
biofourmis.com

See what CB Insights has to offer

Founded Year

2015

Stage

Series C | Alive

Total Raised

$141.85M

Last Raised

$100M | 1 yr ago

About Biofourmis

Biofourmis discovers, develops, and delivers clinically validated software-based therapeutics to provide better outcomes for patients, advanced tools for clinicians to deliver personalized care, technology for pharmaceutical companies to demonstrate value, and cost-effective solutions for payers. Biofourmis has built Biovitals, a personalized AI-powered health analytics platform that predicts clinical exacerbation in advance of a critical event, which is the backbone of its digital therapeutics product pipeline across multiple therapeutic areas including heart failure, oncology, acute coronary syndrome, COPD, and chronic pain.

Biofourmis Headquarter Location

33 Arch Street Floor 17

Boston, Massachusetts, 02110,

United States

Latest Biofourmis News

Health-tech startup Clinikk raises $4 mn in pre-Series A round from MassMutual Ventures, others

Nov 16, 2021

By SHARE Clinikk, a Bengaluru-based insure-tech and health-tech startup on Tuesday raised $4 million in a pre-Series A funding round led by MassMutual Ventures, the company said in a statement. The funding round also saw participation from Kunal Shah, founder, Cred, Rohit M A, co-founder and managing director, Cloudnine Hospitals, Anjali Bansal, founder, Avaana Capital, Stanford Angels & Entrepreneurs, a Stanford Alumni Association group and other individual investors, the company said. Existing investors Times Internet Group, EMV Capital, 500 Startups’ Southeast Asia-focused 500 Southeast Asia, and WEH Ventures also participated in the round. The company will be using the funds to consolidate its product offering and expand its footprint in Bengaluru and in other cities. It also plans to use the funds in hiring and developing its product. “Unfortunately, primary care is often neglected, and because of this, we see huge increases in out-of-pocket expenses. An integrated care model leads to significantly improved health outcomes and more sustainable health insurance pricing,” said Dr Suraj Baliga, co-founder, Clinikk and an orthopedic surgeon. Clinikk, founded in 2018 by Bhavjot Kaur and Baliga, integrates outpatient care and health insurance on its platform. The package that the company offers includes family health insurance coverage and unlimited out-patient department (OPD) consultations delivered digitally. The company claims to have witnessed growth in its retail offering, with more than 10,000 family subscriptions in the full-stack plan, translating into a growth of 30% on month. Clinikk aims to add 20 million subscribers in the top 50 Indian cities by 2025. “Over the next three months, our subscribers will be able to reach a qualified doctor digitally or walk into their nearest Clinikk network care centre in 10 minutes. The entire care -- be it primary, secondary or tertiary -- will be completely cashless, and that's a massive transformation of the Indian healthcare system,” said Kaur. Clinikk had raised $2.4 million in seed capital prior to this round. With this fundraise, the company raised $6.4 million to date the company said. VCCircle, last year, had reported that Clinikk had raised pre-Series A funding in a round led by the US-based early-stage investment firm Emphasis Ventures. MassMutual Ventures’ investment in Clinikk    Meanwhile, for MassMutual Ventures, Clinikk’s investment adds to the multistage global venture capital firm’s portfolio of health-tech startups. In February 2020, MassMutual Ventures had invested in Qure.ai Technologies Pvt. Ltd , a Mumbai-based healthcare-technology startup. MassMutual Ventures also co-led a $35 million Series B funding round in health-tech startup Biofourmis Singapore Pte. Ltd, along with Sequoia Capital India. The US-based venture capital firm, in April this year, had led a pre-Series A funding round in Qapita a software-as-a-service (SaaS) platform focused on equity and transaction management for the private market. “There is a huge opportunity to improve access to. Clinikk’s growth has been very impressive so far,” said Ryan Collins, managing director at MassMutual Ventures.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Biofourmis

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Biofourmis is included in 6 Expert Collections, including Digital Health.

D

Digital Health

11,684 items

Companies developing and enabling evidence-based, software-driven therapeutic interventions to prevent, manage, or treat a medical disorder or disease. (*Scope follows the Digital Therapeutics Alliance definition)

I

Internet of Things ( IoT )

3,149 items

A

Artificial Intelligence

7,904 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.

D

Digital Health 150

300 items

2019's cohort of the most promising digital health startups transforming the healthcare industry

M

Medical Devices

11,607 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Biofourmis Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Biofourmis Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.